Previous 10 | Next 10 |
2023-03-14 10:08:44 ET Gainers: PaxMedica ( PXMD ) +36% . Avid Bioservices ( CDMO ) +25% . Amylyx Pharmaceuticals ( AMLX ) +17% . Euda Health ( EUDA ) +17% . Addex Therapeutics ( ADXN ) +11% . Losers: Rapt Therap...
2023-03-13 19:58:02 ET Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2022 Earnings Conference Call March 13, 2023, 04:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer and Co-Founder Marg...
2023-03-13 18:18:39 ET Amylyx Pharmaceuticals ( NASDAQ: AMLX ) has risen 20% in after-hours trading after posting Q4 2022 results that beat on the. top and bottom lines. Although the company had revenue in the quarter compared to the prior-year period thanks to the lau...
2023-03-13 16:27:13 ET Amylyx Pharmaceuticals press release ( NASDAQ: AMLX ): Q4 GAAP EPS of -$0.65 beats by $0.16 . Revenue of $21.89M beats by $17.17M . Cash, cash equivalents, and short-term investments were $346.9 million at December 31, 2022, compared to $...
Full year product revenue of $22.2 million; commercial launches of RELYVRIO ® in U.S. and ALBRIOZA™ in Canada continue to progress Regulatory review ongoing in the EU Karen Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity ...
2023-03-10 15:00:56 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the following upcoming investor conferences, which are being conducted in a virtual format: Oppenheim...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, following the close of the U.S. financial markets. Amylyx’ senior management team will host a c...
Reata Pharmaceuticals ( NASDAQ: RETA ) lost ~32% on Monday to reach the lowest level in over four months as a key FDA official leaves the agency while the company awaits the U.S. approval for its Friedreich's ataxia ((F.A.)) therapy, omaveloxolone. Earlier in the day, multiple new...
Summary AMLX got relyvrio approved through an interesting set of events. There are questions surrounding high price, low benefit, trial design, and so on. However, simply the high demand from a vocal and very sick patient population may well save the day for the company. I...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...